Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001031412 | SCV001194718 | pathogenic | Ellis-van Creveld syndrome; Curry-Hall syndrome | 2020-03-23 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals with EVC2-related conditions. For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the EVC2 protein. Other variant(s) that disrupt this region (p.Ser1220Argfs*3) have been determined to be pathogenic (PMID: 12571802, 17024374, 19810119, 23220543). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. This variant is a gross deletion of the genomic region encompassing exons 21-22 of the EVC2 gene. The 5' boundary is likely confined to intron 20. The 3' end of this event is unknown as it extends through the termination codon beyond the assayed region for this gene and may encompass additional genes. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated protein product or disrupt mRNA translation. |